Erasca Secures U.S. Patent for Pan-KRAS Inhibitor ERAS-4001 Until 2043
Event summary
- Erasca received U.S. Patent No. 12,552,813 for ERAS-4001, covering composition of matter until at least June 2043.
- ERAS-4001 is an oral, highly potent pan-KRAS inhibitor in Phase 1 trial BOREALIS-1 for KRAS-mutant solid tumors.
- Phase 1 monotherapy data for ERAS-0015 expected in 1H 2026, ERAS-4001 data in 2H 2026.
- ERAS-4001 demonstrated preclinical tumor regression in KRAS-mutant models with favorable ADME/PK properties.
The big picture
This patent strengthens Erasca's position in the competitive RAS-targeting oncology space, where KRAS mutations are found in approximately 25% of all human cancers. The long-term IP protection comes as biotech companies race to develop more effective therapies for these hard-to-treat mutations, with potential first-mover advantages for those securing strong patent positions. The upcoming clinical data will be critical in determining whether Erasca's candidates can deliver on their promising preclinical profiles.
What we're watching
- Patent Strategy
- How Erasca will leverage this long-term IP protection to secure partnerships or maintain competitive advantage in the RAS-targeting space.
- Clinical Execution
- Whether the upcoming Phase 1 data for ERAS-4001 and ERAS-0015 will validate their potential best-in-class profiles in RAS-driven cancers.
- Market Differentiation
- The pace at which Erasca can establish ERAS-4001 as a differentiated therapy against emerging KRAS inhibitors in development.
Related topics